Verona Pharma Plc
(NASDAQ : VRNA)

( )
VRNA After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
CTLTCatalent, Inc. 1.56%82.052.1%$228.74m
SAVACassava Sciences, Inc. 18.13%11.470.0%$208.15m
JAZZJazz Pharmaceuticals Plc 1.11%139.582.4%$169.45m
HZNPHorizon Therapeutics Plc 3.88%78.255.8%$167.25m
MRNSMarinus Pharmaceuticals, Inc. 4.21%11.157.8%$124.96m
CORTCorcept Therapeutics, Inc. 1.88%17.095.5%$120.14m
VRXValeant Pharmaceuticals International, Inc. 0.53%15.3014.1%$90.03m
BHCBausch Health Cos., Inc. 0.53%15.300.0%$61.37m
MYOKMyoKardia, Inc. 2.08%132.721.8%$59.58m
AMRNAmarin Corp. Plc 4.67%3.811.5%$56.78m
ARGXargenx SE 2.26%248.570.0%$56.59m
SAGESAGE Therapeutics, Inc. 3.26%60.828.6%$46.31m
GWPHGW Pharmaceuticals Plc 1.97%100.446.2%$39.53m
AXSMAxsome Therapeutics, Inc. 1.44%77.021.9%$39.11m
ICLRICON plc 2.30%183.144.3%$36.29m

Company Profile

Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. Its lead product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.